Milagen, Inc.

EMERYVILLE, CA · CIK 0001810185 · Medtech · Private

Blood-based cancer screening and recurrence detection diagnostic

milagen.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$6.6M
3 Form D · Jun 2020
76 months since last filing
Contracts
—
No federal contracts on record
Patents
7
1 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raised· 1 of 3 same dayForm D · SEC$1,560,000
Private capital raised· 2 of 3 same dayForm D · SEC$3,300,000
Private capital raised· 3 of 3 same dayForm D · SEC$1,705,000
Form D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1371CYTEQUEST, INC.—$1.2M
1372WearWorks——
1373MITOLUMINATE, LLC——
1374Milagen, Inc.—$6.6M
1375CISION VISION, INC.——
1376Metric Medical Devices, Inc.—$4.4M
1377INSOMA BIO, INC.—$3.3M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Moncef JendoubiExecutive Officer

Patents

USPTO · 1 granted of 7
  • MARKER FOR CANCER DETECTION (BC / or BF9)application
  • Markers For Cancer Detection (BF7)application
  • Device For High Throughput Detection Of Cervical Diseasegranted
  • Biological Marker For Early Cancer Detection And Methods For Cancer Detection (BF819)application
  • MARKER FOR CANCER DETECTION (BC / or BF9)application
  • Markers For Cancer Detection (BF7)application
  • Device And Methods For The Detection Of Cervical Diseaseapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.